Inhibiting the effect of (90)Sr-(90)Y ophthalmic applicators on rat corneal neovascularization induced by sutures.
OBJECTIVE
To investigate a practical technique used to inhibit corneal angiogenesis with a (90)Sr-(90)Y ophthalmic applicator.


METHODS
A (90)Sr-(90)Y ophthalmic applicator was detected with a radioactive nuclide application treatment healthy protection standard. The applicator used was produced through medical dosimetry research; it had a concave applicator add measured the applicator temperature, serviceable humidity range, applicator appearance status, applicator radiation homogeneity, radioautography, and radiological safety of the original applicator surface. A vessel model was established using newborn rats, with sutures around the corneal limbus. Corneal neovascularization (CNV) were observed with a slit lamp. The new vessel length and response area were measured.


RESULTS
Low-dose radiation can inhibit CNV after corneal sutures. The absorbed dose of the applicator (0.046 Gy/s) was safe for the treatment of it. The lengths of new vessels and the areas of new vessels were lower than the new born vessel rat group (P<0.01).


CONCLUSIONS
The optimal radiation dose emitting from the applicator can be safe and potentially used in humans.
Department of Ophthalmology, China-Japan Union Hospital of Jilin University, Changchun 130033, Jilin Province, China.
Hong-Yan
HY
Zhou
Department of Ophthalmology, China-Japan Union Hospital of Jilin University, Changchun 130033, Jilin Province, China.
Shuang
S
Wang
Department of Ophthalmology, China-Japan Union Hospital of Jilin University, Changchun 130033, Jilin Province, China.
Hong
H
Zhang
Department of Ophthalmology, China-Japan Union Hospital of Jilin University, Changchun 130033, Jilin Province, China.
Ling
L
Wang
Department of Ophthalmology, the Second Hospital of Jilin University, Changchun 130033, Jilin Province, China.
Wen-Song
WS
Zhang
cornea; neovascularization; radiation
Phys Med Biol. 2000 Dec;45(12):3589-99
11131186
Can Vet J. 2012 Dec;53(12):1301-7
23729828
Vascul Pharmacol. 2012 Nov-Dec;57(5-6):201-7
22967957
Proc Natl Acad Sci U S A. 2012 Sep 4;109(36):14580-5
22904195
Curr Opin Ophthalmol. 2001 Aug;12(4):242-9
11507336
Acute Card Care. 2011 Mar;13(1):9-13
21244228
Dermatology. 2012;225(1):88-92
22986416
Cardiovasc Diabetol. 2012 Sep 07;11:105
22954171
Annu Rev Biochem. 1986;55:69-102
3017195
Dev Cell. 2012 Sep 11;23(3):587-99
22975327
Int J Exp Pathol. 2009 Jun;90(3):195-221
19563606
Curr Radiopharm. 2012 Jul;5(3):253-63
22697484
Radiat Prot Dosimetry. 2011 Sep;147(1-2):296-9
21831866
J Korean Med Sci. 2016 Feb;31 Suppl 1:S75-87
26908993
Clin Sci (Lond). 2016 May;130(9):683-96
26814205
Front Oncol. 2016 Feb 01;6:15
26870694
Int J Colorectal Dis. 2012 Jul;27(7):879-84
22173715
Int J Radiat Oncol Biol Phys. 2013 Mar 1;85(3):583-97
22975610
Anticancer Drugs. 2012 Jun;23(5):525-33
22357220
PLoS One. 2012;7(7):e41858
22848638
PLoS One. 2015 Dec 31;10(12):e0141925
26720197
Oncol Rep. 2012 Nov;28(5):1633-8
22922737
Int J Radiat Oncol Biol Phys. 2012 Dec 1;84(5):e577-84
22981710
Life Sci. 2012 Sep 17;91(7-8):264-70
22884805
Curr Pharm Des. 2013;19(1):17-28
22950505
Brachytherapy. 2014 Jan-Feb;13(1):1-14
24373763
Int J Inflam. 2015;2015:970890
26839731
Curr Radiopharm. 2012 Jul;5(3):271-87
22642386